- $1.48m
- -$0.21m
- $6.84m
U.S. STOCKS ON THE MOVE-Hasbro, Moderna, CymaBay
Brief: Invo Bioscience And Naya Biosciences Announce Definitive Merger Agreement
Brief: INVO Bioscience- On Sept 29, Co, Steven Shum & Co’s Units Entered Into Revenue Loan And Security Agreement With Decathlon Alpha V LP
Brief: Invo Bioscience Inc Says Board Unanimously Recommends That Company's Shareholders Vote "For" All Proposals
Brief: INVO Closes Acquisition Of Wisconsin Fertility Institute
Brief: INVO Bioscience Announces Pricing Of $4.5 Million Public Offering
Brief: INVO Announces A 120 Reverse Stock Split
Brief: Invo Receives 510(K) FDA Clearance For Expanded Use Of The Invocell Device
Brief: INVO Bioscience Gets Notice Of Delisting From Nasdaq
U.S. RESEARCH ROUNDUP-Anaptysbio, Booking Holdings, Ulta Beauty
Brief: Invo Reports First Quarter 2023 Financial Results
Invo Bioscience Inc Reports Results For The Quarter Ended In December: Earnings Summary
Invo Bioscience Inc Expected To Post A Loss Of 19 Cents A Share: Earnings Preview
Invo Bioscience Inc Expected To Post A Loss Of 19 Cents A Share: Earnings Preview
Brief: Invo Bioscience Inc Says Revenue For The Year Ended December 31, 2022 Is Expected To Decrease By About 80% In 2022 As Compared To 2021 - Filing
Brief: Invo Bioscience Inc Expects Total Revenue In Q4 Of 2022 To Reflect A Sequential Increase Of Approximately 15% To 19%
Brief: Invo Bioscience Announces Closing Of $3.0 Million Registered Direct Offering
Invo Bioscience Inc Expected To Post A Loss Of 19 Cents A Share: Earnings Preview
Brief: Invo Bioscience Announces Pricing Of $3.0 Million Registered Direct Offering Priced At-The-Market